Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Written by Emily J. Thompson, Senior Investment Analyst

RSLS%

Source: Newsfilter

Updated: Aug 13 2025

0mins

Source: Newsfilter

Merger and Nasdaq Listing: Vyome Therapeutics, Inc. will officially list on the Nasdaq under the name Vyome Holdings, Inc. with the ticker symbol "HIND" following its merger with ReShape Lifesciences, effective August 15, 2025.
Focus on Immuno-inflammatory Conditions: The company aims to address significant unmet needs in the immuno-inflammatory disease market, which exceeds $100 billion, leveraging its clinical-stage assets and innovative approaches in healthcare.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Top Growth Stocks to Buy Now: Nvidia, Amazon, Dutch Bros

Bitcoin's Market Cap Exceeds $1.9 Trillion, Potential to Reach $1.2 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch